For periampullary cancers, including adenocarcinoma of the pancreas, ampulla, bile duct, and duodenum, a curative-intent pancreaticoduodenectomy provides the only chance for long-term survival. Adjuvant systemic therapy has been conclusively shown to improve survival after surgery for pancreatic cancer,1 but there is far less convincing evidence regarding the benefit of adjuvant therapy for other periampullary cancers.2 This lack of evidence is because of several factors: the low incidence of nonpancreas periampullary cancers, difficulty determining their exact site of origin, and, for biliary tract cancers, the pooling together of hilar, intrahepatic and extrahepatic cholangiocarcinomas, and gallbladder carcinomas under a single study “umbrella.”3,4 Complicating matters further is that such patients also frequently develop clinically relevant postoperative pancreatic fistulas, hampering their ability to receive timely adjuvant therapy.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Ko AH, Nakakura EK. Adjuvant Therapy for Ampullary Cancer. JAMA Surg. 2019;154(8):715. doi:10.1001/jamasurg.2019.1171
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: